(Q39393492)

11 September 2017

title

In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model (English)

1 reference

11 September 2017

1 reference

7

1 reference

11 September 2017

Alessa Pardo

1

1 reference

11 September 2017

Michael Stöcker

2

1 reference

11 September 2017

Florian Kampmeier

3

1 reference

11 September 2017

Georg Melmer

4

1 reference

11 September 2017

Rainer Fischer

5

1 reference

11 September 2017

Theo Thepen

6

1 reference

11 September 2017

publication date

19 February 2012

1 reference

Cancer Immunology, Immunotherapy

11 September 2017

published in

1 reference

11 September 2017

volume

61

1 reference

11 September 2017

issue

10

1 reference

11 September 2017

page(s)

1617-1626

1 reference

Whole-animal cellular and molecular imaging to accelerate drug development

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Green fluorescent protein as a marker for gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Molecular probes for the in vivo imaging of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Bright far-red fluorescent protein for whole-body imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

FDA drug approval summary: erlotinib (Tarceva) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Cetuximab: from bench to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

FDA drug approval summary: panitumumab (Vectibix).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Immunotoxin therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Immunotoxin treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Nuclear EGFR contributes to acquired resistance to cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1219-3

10.1007/S00262-012-1219-3

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference